The Valley Desk

NCT00309244 · Interventional trial

Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 4-Week Follow-up

Overall registry status Completed

Phase 3

Conditions Diabetes Type 2

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov